U.S. pharma huge copyright scrapped two experimental weight loss capsules very last year—a when-every day tablet, lotiglipron, due to elevated liver enzymes as well as a two times-every day capsule, danuglipron, as a result of solid Unwanted effects—but CEO Albert Bourla has reported